Genmab’s Post

Let’s take the fight against blood cancer to new heights! I am teaming up with The Leukemia & Lymphoma Society at Big Climb! If you would like to join me and Team ZS Associates reach our goal towards creating a world without blood cancer please click on the link: https://lnkd.in/e86Dj7Sh #BigClimb #ClimbConquerCure #BigClimb #ClimbConquerCure. #LetsDoThis!

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/dPW-ansy  #EHA24 #Lymphoma

Fact: Over a million people every year around the world will experience the diagnosis of a blood cancer. During National Blood Cancer Awareness Month, increase your knowledge about Leukemia, Myeloma, and Lymphoma and their need for improved diagnosis, treatment, and research funding. To learn more about blood cancers and how to get involved, visit https://hubs.li/Q02NdScW0 on the National Today website. #BloodCancerAwarenessMonth #diagnostics #Leukemia #Myeloma #Lymphoma

Q&A: How Successful are Bone Marrow Transplants for Lymphoma? - Blood Cancer OncTalk 2023 https://lnkd.in/e6RP45Ev via @YouTube In this video, Drs. Goodman, Phillips, Taneja, and Rajeeve discuss bone transplants in patients with lymphoma, and if there are steps patients can take to improve their success rate. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://lnkd.in/ekmZ-Pe. #Lymphoma #BloodCancer #BoneMarrowTransplant

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/d4be5h5W #EHA24 #Lymphoma

Lymphoma affects millions worldwide. On World Lymphoma Awareness Day, we must work together to: - Raise awareness: Educate yourself and others about lymphoma. - Support research: Fund initiatives driving innovation. - Promote access: Ensure quality cancer care for all. Join us in the fight against lymphoma. #pinncle #pharma #LymphomaAwareness #WorldLymphomaDay #FightLymphoma #CancerResearch #SupportCancerCare #LymphomaWarriors #AwarenessMatters #TogetherAgainstCancer #LymphomaSupport #CancerAwareness

Did you know that non-Hodgkin lymphoma accounts for about 90% of all lymphoma cases diagnosed and according to the American Cancer Society is one of the most common cancers in the U.S. Learn more about non-Hodgkin lymphoma and other cancers here: https://lnkd.in/gHWmf_PH #NonHodgkinLymphoma #LymphomaAwareness #Lymphoma

Ryan Jacobs, the Director of Lymphoma at LEVINE CANCER INSTITUTE - CLEVELAND, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/dGGgc_CW #EHA24 #Lymphoma

Ryan Jacobs, the Director of Lymphoma at Levine Cancer Institute - Cleveland, presents in this MEDtalk an update on his research from the EHA 2023 meeting on AZD-0486, a novel CD19/CD3 T-cell engager used in treating relapsed refractory follicular lymphoma. The update includes patient responses and tolerability information, highlighting findings such as high overall response rates, complete remission rates, and low toxicity with the double step-up dosing method. 🔗Follow along as we cover EHA 2024: https://lnkd.in/d8jmcNPw #EHA24 #Lymphoma

Leukemia and lymphoma are easily confused because they’re both types of blood cancer. Leukemia usually occurs in bone marrow, while lymphoma originates in the lymphatic system and mainly targets lymph nodes and lymph tissue. Source: cancercenter #LeukemiaAwareness #LymphomaAwareness #LeukemiaAndLymphomaAwareness #FightBloodCancer #BloodCancerAwareness #AzaleaHealthTT